Fenbo (FEBO) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
29 Nov, 2025Company overview and business model
Operates as a holding company with subsidiaries in Hong Kong and China, specializing in OEM/ODM manufacturing of personal care electric appliances, mainly hair styling products, and toys for overseas markets.
Sole customer is Spectrum Brands, for whom it manufactures Remington-branded products sold in Europe, the US, and Latin America.
Production capacity exceeds three million units per year, with manufacturing based in Shenzhen, China.
Business model focuses on OEM/ODM, with plans to develop own branded products and expand into new markets.
Financial performance and metrics
2023 revenue was HK$119.1 million (US$15.2 million), nearly flat year-over-year.
Net loss for 2023 was HK$1.5 million (US$0.2 million), compared to net income of HK$8.7 million in 2022, mainly due to a one-off gain in 2022.
Gross profit margin improved to 18.6% in 2023 from 15.7% in 2022.
Cash balance at year-end 2023 was HK$46.3 million (US$5.9 million); working capital was HK$54.9 million (US$7.0 million).
All revenue in recent years derived from a single customer.
Use of proceeds and capital allocation
Net proceeds from the offering (estimated at $4.29 million if fully sold) will be allocated: 20% to R&D, 40% to own brand development, 30% to sales team formation, and 10% to working capital.
Management has broad discretion over use of proceeds.
Latest events from Fenbo
- Emerging growth issuer offers shares and warrants, emphasizing compliance and financial stability.FEBO
Registration Filing30 Nov 2025 - IPO proceeds target R&D and brand growth, but extreme customer concentration and regulatory risks remain.FEBO
Registration Filing29 Nov 2025 - Offering up to $5M in shares/warrants, with all revenue from one customer and high regulatory risk.FEBO
Registration Filing29 Nov 2025 - IPO targets $5M to fund R&D and branded expansion, but faces single-customer and regulatory risks.FEBO
Registration Filing29 Nov 2025 - Revenue up 14.2% but higher costs drove a net loss; IPO completed for future expansion.FEBO
H1 202413 Jun 2025 - 2024 revenue rose 11.6%, but net loss deepened amid rising costs and single-customer risk.FEBO
H2 20259 Jun 2025